Czech National Bank Raises Holdings in Cencora, Inc. (NYSE:COR)

Czech National Bank boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,025 shares of the company’s stock after acquiring an additional 2,489 shares during the quarter. Czech National Bank’s holdings in Cencora were worth $8,543,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of COR. Concord Wealth Partners acquired a new position in shares of Cencora in the 3rd quarter valued at $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora in the second quarter worth about $36,000. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the third quarter worth about $41,000. Fairscale Capital LLC purchased a new stake in shares of Cencora during the 2nd quarter worth about $54,000. Finally, Modus Advisors LLC purchased a new position in shares of Cencora in the 4th quarter valued at about $54,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Up 1.8 %

COR opened at $240.36 on Wednesday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company’s 50 day simple moving average is $237.95 and its two-hundred day simple moving average is $233.65. The firm has a market capitalization of $46.46 billion, a price-to-earnings ratio of 32.01, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $253.27.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is 29.29%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COR. Barclays increased their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Evercore ISI lifted their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 94,696 shares of company stock worth $22,862,734 in the last three months. 15.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.